Clinical Study
The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients
Table 2
Comparison of baseline values in groups segregated by the course of IMT.
| | Characteristics | Nonprogressors () | Progressors () |
| | Gender, male (%) | 14 (67) | 30 (65) | | Age, years | 40.1 (1.1) | 39.9 (1.1) | | BMI, kg/m2 | 22.9 (0.2) | 23.1 (0.2) | | Systolic blood pressure, mm Hg | 119.9 (2.7) | 115.9 (1.9) | | Diastolic blood pressure, mm Hg | 79.6 (1.4) | 77.3 (1.3) | | Smoking, n (%) | 13 (62) | 30 (65) | | TDF-FTC-based therapy, n (%) | 7 (33) | 28 (61)* | | CD4+ T cell count, cells/μL | 463.2 (46.1) | 469.9 (19.3) | | Total cholesterol, mmol/L | 4.79 (0.3) | 5.02 (0.4) | | HDL cholesterol, mmol/L | 1.18 (0.2) | 1.17 (0.1) | | LDL cholesterol, mmol/L | 2.66 (0.3) | 2.79 (0.4) | | Triglycerides, mmol/L | 2.48 (0.3) | 2.51 (0.3) | | Glucose, mmol/L | 5.40 (0.4) | 5.41 (0.4) | | Delta IMT, mm | −0.05 (0.01) | 0.22 (0.01)* |
|
|
Data are the mean (SEM) unless otherwise indicated. a with respect to nonprogressors BMI, body-mass index.
|
